Please login to the form below

Not currently logged in
Email:
Password:

BlackThorn Therapeutics appoints CEO

Gregory Vontz joins from Topica Pharmaceuticals

BlackThorn Therapeutics Gregory VontzSan Francisco, US-based biotech BlackThorn Therapeutics has appointed Gregory Vontz as its new chief executive officer.

Vontz brings over 30 years of biotech and pharma industry experience to the role, joining from fungal infection specialist Tropica Pharmaceuticals where he also served as chief executive.

Prior to this, Vontz was president and chief operating officer of Connetics Corporation, spent 12 years in a series of senior marketing and product development roles at Genentech, and worked in sales and sales management at Merck & Co.

Dr Mark Corrigan, chairman of the board at BlackThorn, said: “On behalf of the Board and the BlackThorn team, I am pleased to welcome Greg as our new chief executive officer.

“His experience as a biotech executive, record of successful drug development and strategic transactions will serve BlackThorn well in advancing the company's mission to develop new treatments for patients suffering from neurobehavioral disorders.”

17th February 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...